2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related

Interleukin Related

IL

Interleukin Related

Related Products

PDF 1.53 MB

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Interleukin Related Isoform Specific Products:

Interleukin Related Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100754A
    Ritlecitinib (malonate)
    		Inhibitor
    Ritlecitinib (PF-06651600) malonate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib malonate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib malonate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE).
    Ritlecitinib (malonate)
  • HY-172451
    MC4762
    		Inhibitor
    MC4762 is an inhibitor of NOX2 and MAOB, with IC50 values of 0.155 μM and 0.182 μM, respectively. MC4762 has anti-inflammatory activity, can inhibit the production of ROS, and downregulate the expression of pro-inflammatory cytokines iNOS, IL-1β, and IL-6.
    MC4762
  • HY-107909
    Theophylline sodium glycinate
    		Inducer
    Theophylline (1,3-Dimethylxanthine) sodium glycinate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline sodium glycinate inhibits PDE3 activity to relax airway smooth muscle. Theophylline sodium glycinate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline sodium glycinate induces apoptosis. Theophylline sodium glycinate can be used for asthma and chronic obstructive pulmonary disease (COPD) research.
    Theophylline sodium glycinate
  • HY-P990933
    Ocankitug
    HY-P990933 is an TSLP-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Ocankitug
  • HY-P99515
    Xeligekimab
    		Inhibitor
    Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade.
    Xeligekimab
  • HY-B0010C
    (S,S)-Formoterol
    		Activator
    (S,S)-Formoterol ((+)-Formoterol) is a (S,S)-enantiomer of Formoterol. (S,S)-Formoterol can promote asthma by enhancing IL-4 production in mast cells of the asthmatic airway.
    (S,S)-Formoterol
  • HY-P99499
    Cetrelimab
    		Activator ≥99.0%
    Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo.
    Cetrelimab
  • HY-P990937
    Pacibekitug
    		Inhibitor
    HY-P990937 is an IL6-targeting IgG2κ type human antibody, the recommed isotype control is Human IgG2 kappa, Isotype Control (HY-P99002).
    Pacibekitug
  • HY-P991019
    Recibokibart
    		Inhibitor
    HY-P991019 is an IL1RL2-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Recibokibart
  • HY-P99869
    Ebdarokimab
    		Inhibitor
    Ebdarokimab (AK101) is a humanized IgG1-κ antibody, usually expressed in CHO (Chinese Hamster Ovary) cells.
    Ebdarokimab
  • HY-P991035
    Turenkibart
    		Inhibitor
    HY-P991035 is an IL17A-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Turenkibart
  • HY-P990910
    Comekibart
    		Inhibitor
    HY-P990910 is an IL4R-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Comekibart
  • HY-P990691
    Vilamakitug
    		Inhibitor
    Vilamakitug (XB-2001) is an anti-IL-1α human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Vilamakitug
  • HY-18725
    P2X7-IN-2
    		Inhibitor
    P2X7-IN-2 (compound 58) is a P2X7 receptor inhibitor. P2X7-IN-2 inhibits IL-Iβ release with an IC50 value of 0.01 nM. P2X7-IN-2 can be used for the research of autoimmunity, inflammation and cardiovascular disease.
    P2X7-IN-2
  • HY-14908A
    Vidofludimus hemicalcium
    		Inhibitor
    Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR.
    Vidofludimus hemicalcium
  • HY-P991030
    Tabirafusp alfa
    		Inhibitor
    HY-P991030 is an IL-6-targeting Fusion Protein.
    Tabirafusp alfa
  • HY-141599
    Camidanlumab tesirine
    		Inhibitor
    Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines.
    Camidanlumab tesirine
  • HY-P991005
    Larnefpendekin alfa
    		Inhibitor
    HY-P991005 is an IL-15RA-targeting Fusion Protein.
    Larnefpendekin alfa
  • HY-132831A
    Selnoflast calcium
    		Inhibitor
    Selnoflast calcium (RO7486967 calcium), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast calcium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast calcium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease.
    Selnoflast calcium
  • HY-B0809A
    Theophylline monohydrate
    		Inducer
    Theophylline (1,3-Dimethylxanthine) monohydrate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) monohydrate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) monohydrate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) monohydrate induces apoptosis. Theophylline (1,3-Dimethylxanthine) monohydrate can be used for asthma and chronic obstructive pulmonary disease (COPD) research.
    Theophylline monohydrate
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Interleukin Related Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.